Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM ESTCompany ParticipantsJohn Quisel - CEO, President ...

Silence Therapeutics advanced its RNAi drug for polycythemia vera, shared new Phase 2 trial updates, and reaffirmed a strong ...

Anti-interleukins and JAK inhibitors are linked to a reduced serious infection risk among patients with ulcerative colitis.

AbbVie’s Rinvoq (upadacitinib) remains the leading JAK inhibitor across all three indications, maintaining strong growth despite persistent safety concerns tied to the JAK class. Rheumatologists ...

A systematic review reports that monoclonal antibodies and JAK inhibitors can be effective in the treatment and clearance of ...

Approved JAK inhibitors such as ruxolitinib and fedratinib target the JH1 kinase domain, offering symptomatic relief but lacking selectivity for the mutant form. This non-selective inhibition disrupts ...

Eilean Therapeutics LLC is a privately held biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small-molecule therapies that target genetic and ...

In patients who had failed four or more prior therapies, the difference was 29%. In a particularly difficult-to-treat group – those whose disease had not responded to JAK inhibitors – the response ...

Researchers conducted a multicentric real-world retrospective study of 241 patients across 11 dermatologic centres in the Czech Republic between January 2022 and September 2024. Participants with ...

Dr. Prithviraj Bose discussed the current treatment landscape for myeloproliferative neoplasms, a group of rare blood cancers; he focused on myelofibrosis. Dr. Prithviraj Bose, a professor in the ...